Synopsis of recent research by authors named "Marcia Rupnow"
- Marcia Rupnow's research primarily focuses on the effectiveness of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in improving glycemic control and associated outcomes in patients with type 2 diabetes mellitus (T2DM), with many studies evaluating real-world settings and demographic impacts.
- Her findings reveal that canagliflozin shows promising results in lowering hemoglobin A1C levels, improving quality measures, and addressing healthcare disparities, particularly among different ethnic groups such as Hispanic/Latino patients.
- Rupnow's work also includes economic evaluations comparing canagliflozin to other antihyperglycemic agents like sitagliptin, shedding light on both clinical outcomes and cost efficiency, which is crucial for managing type 2 diabetes in a healthcare setting.
